À¯·´ÀÇ DNA ÃßÃâ, ºÐ¸®, Á¤Á¦ ½ÃÀå ¿¹Ãø(2030³â) : Áö¿ªº° ºÐ¼® - À¯Çü, ¹æ¹ý, »ùÇà À¯Çü, °ø±Þ¿ø, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚº°
Europe DNA Extraction, Isolation, and Purification Market Forecast to 2030 - Regional Analysis - by Type, Method, Sample Type, Source, Application, and End User
»óǰÄÚµå : 1463681
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2024³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 163 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,450 £Ü 5,014,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 4,450 £Ü 6,467,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,450 £Ü 7,921,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

À¯·´ÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº 2022³â¿¡ 6¾ï 6,731¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2030³â¿¡´Â 13¾ï 396¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2022-2030³âÀÇ CAGRÀº 8.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

À¯ÀüüÇÐ ¿¬±¸°³¹ßÀÇ Áõ°¡°¡ À¯·´ÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀ» Ȱ¼ºÈ­

À¯ÀüüÇÐÀº À¯Àüº´ Áø´Ü°ú Ä¡·á¸¦ °³¼±ÇÏ´Â Å« °¡´É¼ºÀ» ³»Æ÷Çϰí ÀÖ½À´Ï´Ù. °Ô³ð DNA ÃßÃâÀº »ý¸í°úÇп¡¼­ °¡Àå ÀϹÝÀûÀÎ ÀýÂ÷ Áß ÇϳªÀÔ´Ï´Ù. °Ô³ð DNA´Â »ý¹°ÀÇ À¯Àü ¹°Áú°ú ¿°»öü ¹°ÁúÀ» ¸ðµÎ Æ÷ÇÔÇϰí ÀÖÀ¸¸ç, »ý¸í À¯Áö¿¡ ÇÊ¿äÇÑ ¸ðµç ÄÄÆ÷³ÍÆ®¸¦ ¾ÏȣȭÇϰí ÀÖ½À´Ï´Ù. ¿°±â¼­¿­ °áÁ¤, ¿°±â¼­¿­ µ¥ÀÌÅÍ Á¶¸³ ¹× ºÐ¼®À» À§ÇÑ ÃÖ÷´Ü ±â¼úÀÇ ÃâÇöÀ¸·Î ÀÇÇÐ ¹× ±âŸ °úÇÐ ºÐ¾ß¿¡¼­ À¯ÀüüÇÐÀÇ Á߿伺ÀÌ ´õ¿í Ä¿Áú °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ¿¡ µû¶ó Á¤ºÎ ¹× ºñÁ¤ºÎ ±â°üÀº °Ô³ð ¿¬±¸¸¦ ÃËÁøÇϱâ À§ÇÑ ±¸»óÀ» ÃëÇϰí ÀÖÀ¸¸ç, 2022³â 12¿ù ¿µ±¹ Á¤ºÎ´Â ¼¼°è ÃÖ°í ¼öÁØÀÇ °Ô³ð ÀÇ·á ½Ã½ºÅÛÀ» ±¸ÃàÇÏ°í ±¹°¡ÀÇ °Ç°­ °á°ú¸¦ °³¼±ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃá ÇÁ·ÎÁ§Æ®¸¦ Áö¿øÇϱâ À§ÇØ ÀÚ±ÝÀ» Áö¿øÇÑ´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ÀÚ±Ý Áö¿øÀ¸·Î ¿¬±¸ÀÚµéÀº »ç¶÷µéÀÇ DNA ¿¬±¸¸¦ ÇÙ½É ¾÷¹«·Î ÇÏ´Â ¼¼°è ÃÖ°í ¼öÁØÀÇ °Ô³ð ÀǷḦ Á¦°øÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

À¯·´ DNA ÃßÃâ, ºÐ¸® ¹× Á¤Á¦ ½ÃÀå °³¿ä

À¯·´ÀÇ DNA ÃßÃâ, ºÐ¸®, Á¤Á¦ ½ÃÀåÀº µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ±âŸ À¯·´À¸·Î ³ª´¹´Ï´Ù. ±¹Á¦¹«¿ª±¹(ITA)¿¡ µû¸£¸é µ¶ÀÏÀÇ ÀÇ·á±â±â ½ÃÀåÀº ¿¬°£ 358¾ï ´Þ·¯·Î À¯·´ Àüü ÀÇ·á±â±â ½ÃÀåÀÇ 25.6%¸¦ Â÷ÁöÇϰí ÀÖÀ¸¸ç, ITA¿¡ µû¸£¸é µ¶ÀÏÀº ¹Ì±¹, ÀϺ»¿¡ ÀÌ¾î ¼¼°è 3À§ÀÇ ÀÇ·á ±â¼ú ½ÃÀåÀ¸·Î À¯·´¿¡¼­ °¡Àå Å« ½ÃÀå ±Ô¸ðÀÔ´Ï´Ù. ¼¼°è¾Ï¿¬±¸±â±Ý(WCRF) ÀÎÅͳ»¼Å³Î¿¡ µû¸£¸é 2020³â µ¶ÀÏ¿¡¼­ 538,140¸íÀÇ ½Å±Ô ¾ÏȯÀÚ°¡ ¹ß»ýÇÏ¿© ¿¬·É Ç¥ÁØÈ­À²Àº 10¸¸ ¸í´ç 281.9¸íÀ̸ç, GLOBOCAN 2020¿¡ µû¸£¸é µ¶ÀÏÀº À¯¹æ¾Ï, Àü¸³¼±¾Ï, Æó¾Ï, ´ëÀå¾ÏÀÇ À¯º´·üÀÌ ³ôÀº ±¹°¡ÀÔ´Ï´Ù. ÀÔ´Ï´Ù. µû¶ó¼­ ¾Ï°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇÑ °Ç°­ ÀÎ½Ä Áõ°¡´Â µ¶ÀÏ¿¡¼­ Áø´Ü ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä¸¦ À¯¹ßÇÏ¿© DNA ÃßÃâ, ºÐ¸® ¹× Á¤Á¦ ½ÃÀå¿¡ ÀÌÀÍÀ» °¡Á®´ÙÁÖ¾ú½À´Ï´Ù. ¿µ±¹ Åë°èû(ONS)ÀÇ º¸°í¼­¿¡ µû¸£¸é ¿µ±¹ Àα¸´Â 2021³â 6,710¸¸ ¸í¿¡¼­ 2030³â Áß¹Ý 6,920¸¸ ¸íÀ¸·Î 2020³â¿¡¼­ 2030³â »çÀÌ¿¡ 3.2%ÀÇ ºñÀ²·Î 210¸¸ ¸í Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àα¸ Áõ°¡´Â ±×¿¡ µû¸¥ Áúº´, À¯Àü¼º Áúȯ, ¾ÏÀÇ À¯º´·ü Áõ°¡¸¦ ¹Ý¿µÇÏ¿© Áø´Ü ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¸¦ °¡Á®¿À°í, WCRF ÀÎÅͳ»¼Å³Î¿¡ µû¸£¸é ¿µ±¹Àº Àα¸ 10¸¸ ¸í´ç ¾Ï ¹ßº´·üÀÌ 296.1¸íÀ¸·Î »ó´çÈ÷ ³ôÀ¸¸ç, 2020³â¿¡´Â 409,228¸íÀÌ »õ·Î ¹ßº´ÇÒ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. Gene People UK(Genetic Disease UK)¿¡ µû¸£¸é ¾î¸°ÀÌ 25¸í Áß 1¸í(4%)ÀÌ À¯Àü¼º ÁúȯÀ» ¾Î°í ÀÖÀ¸¸ç, ¿µ±¹¿¡¼­´Â ¸Å³â 3¸¸ ¸íÀÇ ¿µÀ¯¾Æ¿Í ¾î¸°À̰¡ »õ·Ó°Ô À¯Àü¼º Áúȯ Áø´ÜÀ» ¹Þ°í ÀÖ´Ù°í ÇÕ´Ï´Ù.ÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é Áö³­ ¼ö½Ê³â°£ ÇÁ¶û½º´Â ÇãÇ÷¼º ½ÉÀ庴, ¾ËÃ÷ÇÏÀ̸Ӻ´, ³úÁ¹Áß, Æó¾Ï, ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD)À¸·Î ÀÎÇÑ »ç¸ÁÀÚ°¡ °¡Àå ¸¹Àº ±¹°¡·Î º¸°íµÇ¾úÀ¸¸ç, WCRF ÀÎÅͳ»¼Å³Î¿¡ µû¸£¸é 2020³â ÇÁ¶û½º´Â Àα¸ 10¸¸ ¸í´ç 320.1¸íÀÇ ¾Ï ȯÀÚ°¡ ¹ß»ýÇÑ´Ù, 422,828¸íÀÇ ½Å±Ô ȯÀÚ ¹ß»ýÀ̶ó´Â À¯ÀǹÌÇÑ ¹ßº´·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. ÀÌó·³ ³ôÀº ¾Ï ¹ßº´·ü°ú »ý»ê¼ºÀÌ ³ôÀº ÀÇ·á±â±â »ê¾÷Àº À¯·´¿¡¼­ DNA ÃßÃâ, ºÐ¸®, Á¤Á¦¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ ºÒ·¯ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù.

À¯·´ÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀÇ ¸ÅÃâ°ú 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

À¯·´ÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå ¼¼ºÐÈ­

À¯·´ÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº À¯Çü, ¹æ¹ý, »ùÇà À¯Çü, ¼Ò½º, ¾ÖÇø®ÄÉÀ̼Ç, ÃÖÁ¾»ç¿ëÀÚ, ±¹°¡¿¡ ±â¹ÝÇÏ¿© ¼¼ºÐÈ­µË´Ï´Ù.

À¯Çüº°·Î´Â À¯·´ÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº ŰƮ, ±â±â, ½Ã¾àÀ¸·Î ºÐ·ùµË´Ï´Ù. 2022³â À¯·´ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº ŰƮ ºÐ¾ß°¡ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

¹æ¹ýº°·Î´Â À¯·´ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº È­ÇÐÀû ¹æ¹ý°ú ¹°¸®Àû ¹æ¹ýÀ¸·Î 2ºÐµË´Ï´Ù. 2022³â À¯·´ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå Á¡À¯À²Àº È­ÇÐÀû ¹æ¹ýÀÌ Å®´Ï´Ù. È­ÇÐÀû ¹æ¹ýÀº ÇÑÃþ ´õ Æä³î Ŭ·Î·ÎÆ÷¸§, ½Ç¸®Ä« °Ö, ÇÁ·ÎÅ×À̳ªÁ¦, ±âŸ·Î ¼¼ºÐÈ­µË´Ï´Ù. ¹°¸®Àû ¹æ¹ýÀº Àڱ⠺ñÁî¿Í Á¾ÀÌ·Î ÇÑÃþ ´õ ¼¼ºÐÈ­µË´Ï´Ù.

»ùÇÃÀÇ À¯Çü º°·Î º¸¸é À¯·´ÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº Ç÷¾×, ü¾×, ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2022³â À¯·´ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå Á¡À¯À²Àº Ç÷¾× ºÎ¹®ÀÌ ÃÖ´ë.

°ø±Þ¿øº°·Î´Â À¯·´ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº °Ô³ð°ú ¹Ì»ý¹°·Î ±¸ºÐµË´Ï´Ù. °Ô³ð ºÎ¹®Àº 2022³â À¯·´ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå¿¡¼­ º¸´Ù Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¹Ì»ý¹° ºÎ¹®Àº ÇÑÃþ ´õ ¼¼±Õ°ú ¹ÙÀÌ·¯½º·Î ¼¼ºÐÈ­µË´Ï´Ù.

¿ëµµ¿¡ ±â¹ÝÇÏ¿© À¯·´ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº PCR °Ë»ç, Â÷¼¼´ë ½ÃÄö½Ì, ¸¶ÀÌÅ©·Î¾î·¹ÀÌ, ±âŸ·Î ºÐ·ùµË´Ï´Ù. Â÷¼¼´ë ½ÃÄö½Ì ºÎ¹®ÀÌ 2022³â À¯·´ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå¿¡¼­ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. PCR °Ë»ç ºÎ¹®Àº ¶ÇÇÑ qPCR, ¸ÖƼÇ÷º½º PCR, 16S PCR, ±âŸ·Î ¼¼ºÐÈ­µË´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î´Â À¯·´ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº Áø´Ü ¼¾ÅÍ¡¤¿¬±¸¼Ò, Á¦¾à¡¤¹ÙÀÌ¿À Á¦¾àȸ»ç, CRO, ±âŸ·Î ±¸ºÐµË´Ï´Ù. Áø´Ü ¼¾ÅÍ¿Í ¿¬±¸½Ç ºÎ¹®Àº 2022³â¿¡ ÃÖ´ë À¯·´ DNA ÃßÃâ, ºÐ¸®, Á¤Á¦ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î´Â À¯·´ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº ¿µ±¹, µ¶ÀÏ, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, º£³×·è½º, ¿À½ºÆ®¸®¾Æ, ±âŸ À¯·´À¸·Î ºÐ·ùµË´Ï´Ù. 2022³â À¯·´ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀåÀº ¿µ±¹ÀÌ Áö¹èÀûÀ̾ú½À´Ï´Ù.

Bio-Rad Laboratories Inc, Danaher Corp, GE HealthCare Technologies Inc, F. Hoffmann-La Roche Ltd, Agilent Technologies Inc, Qiagen NV, Merck KGaA, Illumina Inc, Takara Bio Inc, Thermo Fisher Scientific Inc, Molzym GmbH &Co KG´Â À¯·´ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå¿¡¼­ »ç¾÷À» ¿î¿µÇϰí ÀÖ´Â ´ë±â¾÷ÀÇ ÀϺÎÀÔ´Ï´Ù.

¸ñÂ÷

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå À¯·´ÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå - ÁÖ¿ä »ê¾÷ ¿ªÇÐ

Á¦5Àå DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå : À¯·´ ½ÃÀå ºÐ¼®

Á¦6Àå À¯·´ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå - 2030³â±îÁöÀÇ ¸ÅÃâ°ú ¿¹Ãø - À¯Çüº°

Á¦7Àå À¯·´ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå : 2030³â±îÁöÀÇ ¸ÅÃâ°ú ¿¹Ãø : ¹æ¹ýº°

Á¦8Àå À¯·´ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå : 2030³â±îÁöÀÇ ¸ÅÃâ°ú ¿¹Ãø : »ùÇà À¯Çüº°

Á¦9Àå À¯·´ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå : 2030³â±îÁöÀÇ ¸ÅÃâ°ú ¿¹Ãø : °ø±Þ¿øº°

Á¦10Àå À¯·´ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå : 2030³â±îÁöÀÇ ¸ÅÃâ°ú ¿¹Ãø : ¿ëµµº°

Á¦11Àå À¯·´ÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå - 2030³â±îÁöÀÇ ¸ÅÃâ°ú ¿¹Ãø - ÃÖÁ¾»ç¿ëÀÚº°

Á¦12Àå À¯·´ÀÇ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå : 2030³â±îÁöÀÇ ¸ÅÃâ°ú ¿¹Ãø : ±¹°¡º° ºÐ¼®

Á¦13Àå À¯·´ DNA ÃßÃ⡤ºÐ¸®¡¤Á¤Á¦ ½ÃÀå - ¾÷°è »óȲ

Á¦14Àå ±â¾÷ °³¿ä

Á¦15Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Europe DNA extraction, isolation, and purification market was valued at US$ 667.31 million in 2022 and is expected to reach US$ 1,303.96 million by 2030; it is estimated to grow at a CAGR of 8.7% from 2022 to 2030.

Rising R&D in Genomics Fuels the Europe DNA Extraction, Isolation, and Purification Market

Genomics holds significant potential for improved diagnostics and treatment of genetic diseases. Genomic DNA extraction is one of the most common procedures in the life sciences. Genomic DNA contains all of an organism's genetic and chromosomal material and encodes all of the components required for life. The emergence of cutting-edge technologies for sequencing, and assembly and analysis of sequenced data is likely to strengthen the importance of genomics in medicine and other branches of science. Thus, government and nongovernment agencies are taking initiatives to boost genomic research. In December 2022, the Government of UK announced funding to support projects focusing on building the world's most advanced genomic healthcare system and improve health outcomes in the country. The funding enabled researchers to provide world-class genomic healthcare, which involves the study of people's DNA as a core job.

Europe DNA Extraction, Isolation, and Purification Market Overview

The DNA extraction, isolation, and purification market in Europe is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. According to the International Trade Administration (ITA), the German medical device market accounts for ~US$ 35.8 billion annually, and it occupies ~25.6% of the total European medical device market. As per ITA, Germany ranks third among the largest medical technology markets in the world, after the US and Japan, and by far, the largest European market. According to the World Cancer Research Fund (WCRF) International, Germany had a significant incidence age-standardized rate of 281.9 cancer cases per 100,000 in 2020 as the country recorded 538,140 new cases. GLOBOCAN 2020 stated that Germany has a high prevalence rate of breast, prostate, lung, and colorectum cancer. Thus, the rising health awareness due to the elevating prevalence of chronic diseases such as cancer triggers the demand for diagnostics systems in Germany, which benefits the DNA extraction, isolation, and purification market. The Office for National Statistics (ONS) reported that population in the UK is expected to reach 69.2 million by mid-2030 from 67.1 million in 2021, recording an expansion of 2.1 million at a rate of 3.2% during 2020-2030. The population growth would reflect a subsequent increase in the prevalence of diseases, genetic disorders, and cancer cases, resulting in higher demand for diagnostics. According to the WCRF International, the UK had a significant incidence age-standardized rate of 296.1 cancer cases per 100,000, with 409,228 new cases in 2020. As per Gene People UK (Genetic Disorders UK), ~1 in 25 children (4%) is affected by a genetic condition, which means 30,000 infants and children are newly diagnosed with genetic disorders in the UK annually. According to the Global Burden of Disease (GBD) data published in 2020, over the past decades, France has reported the most deaths due to ischemic heart disease, Alzheimer's disease, stroke, lung cancer, and chronic obstructive pulmonary disease (COPD). As per the WCRF International, the country had a significant incidence age-standardized rate of 320.1 cancer cases per 100,000, with 422,828 new cases, in 2020. Thus, high cancer prevalence rates and the highly productive medical device industry trigger the demand for DNA extraction, isolation, and purification methods in Europe.

Europe DNA Extraction, Isolation, and Purification Market Revenue and Forecast to 2030 (US$ Million)

Europe DNA Extraction, Isolation, and Purification Market Segmentation

The Europe DNA extraction, isolation, and purification market is segmented based on type, method, sample type, source, application, end user, and country.

Based on type, the Europe DNA extraction, isolation, and purification market is categorized into Kits, instrument, and reagent. The kits segment held the largest Europe DNA extraction, isolation, and purification market share in 2022.

In terms of method, the Europe DNA extraction, isolation, and purification market is bifurcated into chemical method and physical method. The chemical method segment held a larger Europe DNA extraction, isolation, and purification market share in 2022. The chemical method is further subsegmented into phenol chloroform, silica gel, proteinase, and others. The physical method is further subsegmented into magnetic bead and paper.

By sample type, the Europe DNA extraction, isolation, and purification market is segmented into blood, body fluid, and others. The blood segment held the largest Europe DNA extraction, isolation, and purification market share in 2022.

By source, the Europe DNA extraction, isolation, and purification market is segmented into genomic and microbial. The genomic segment held a larger Europe DNA extraction, isolation, and purification market share in 2022. The microbial segment is further subsegmented into bacteria and virus.

Based on application, the Europe DNA extraction, isolation, and purification market is categorized into PCR test, next generation sequencing, micro array, and others. The next generation sequencing segment held the largest Europe DNA extraction, isolation, and purification market share in 2022. The PCR test segment is further subsegmented into qPCR, multiplex PCR, 16S PCR, and others.

By end-user, the Europe DNA extraction, isolation, and purification market is segmented into diagnostic center and research laboratories, pharmaceutical and biopharmaceutical companies, CROs, and others. The diagnostic center and research laboratories segment held the largest Europe DNA extraction, isolation, and purification market share in 2022.

Based on country, the Europe DNA extraction, isolation, and purification market is categorized into the UK, Germany, France, Italy, Spain, Benelux, Austria, and the Rest of Europe. The UK dominated the Europe DNA extraction, isolation, and purification market in 2022.

Bio-Rad Laboratories Inc, Danaher Corp, GE HealthCare Technologies Inc, F. Hoffmann-La Roche Ltd, Agilent Technologies Inc, Qiagen NV, Merck KGaA, Illumina Inc, Takara Bio Inc, Thermo Fisher Scientific Inc, and Molzym GmbH & Co KG are some of the leading companies operating in the Europe DNA extraction, isolation, and purification market.

Table Of Contents

Table of Content

1. Introduction

2. Executive Summary

3. Research Methodology

4. Europe DNA Extraction, Isolation, and Purification Market - Key Industry Dynamics

5. DNA Extraction, Isolation, and Purification Market - Europe Market Analysis

6. Europe DNA Extraction, Isolation, and Purification Market - Revenue and Forecast to 2030 - by Type.

7. Europe DNA Extraction, Isolation, and Purification Market - Revenue and Forecast to 2030 - by Method.

8. Europe DNA Extraction, Isolation, and Purification Market - Revenue and Forecast to 2030 - by Sample Type

9. Europe DNA Extraction, Isolation, and Purification Market - Revenue and Forecast to 2030 - by Source.

10. Europe DNA Extraction, Isolation, and Purification Market - Revenue and Forecast to 2030 - by Application

11. Europe DNA Extraction, Isolation, and Purification Market - Revenue and Forecast to 2030 - by End User

12. Europe DNA Extraction, Isolation, and Purification Market - Revenue and Forecast to 2030 - Country Analysis

13. Europe DNA Extraction, Isolation, and Purification Market-Industry Landscape

14. Company Profiles

15. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â